神經學生物標記市場Neurology Biomarkers Market
完整報告名稱與涵蓋範圍
報告摘要
The Neurology Biomarkers Market encompasses the research, development, and commercialization of biological indicators used to detect, diagnose, monitor, and predict neurological diseases and therapeutic responses. This market includes molecular, imaging, physiological, and genetic biomarkers applied across conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Key purchasers include pharmaceutical and biotechnology companies, diagnostic laboratories, and academic research institutions, all seeking to advance drug discovery, facilitate clinical trials, and enable personalized medicine approaches in neurological care.
The market is estimated at $2.4 Bn in 2025 and is forecast to reach $8.2 Bn in 2035, growing at a CAGR of 13.1% from 2025 to 2035. Demand is driven by the rising prevalence of neurological diseases and increased R&D funding for neurological therapies, alongside technological advancements in biomarker identification. However, high development and validation costs, coupled with a lack of standardization, present restraints to market expansion.
The market is segmented by Type (e.g., Amyloid Beta, Tau Protein), Technology (e.g., Immunoassays, Mass Spectrometry), Application (e.g., Alzheimer's Disease, Parkinson's Disease), End-User (e.g., Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories), Source (e.g., Cerebrospinal Fluid, Blood), and Product & Service (e.g., Assay Kits, Analyzers & Instruments). Key regions include North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Leading companies include Quanterix, C2N Diagnostics, and Denali Therapeutics. The full report provides detailed analysis across these segments and regions.
Market-Reports.com estimates the Neurology Biomarkers market at $2.4 Bn in 2025 and forecasts $8.2 Bn by 2035, a compound annual growth rate (CAGR) of 13.1%. The forecast is given in conservative, base and optimistic scenarios.
The report segments the market by type (Amyloid Beta Biomarkers, Tau Protein Biomarkers, Alpha-Synuclein Biomarkers, Neurofilament Light Chain Biomarkers, Cerebrospinal Fluid Biomarkers, Blood Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers); technology (Immunoassays, Mass Spectrometry, Chromatography, Next-Generation Sequencing, Polymerase Chain Reaction, Flow Cytometry, In Situ Hybridization); application (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Huntington's Disease, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury, Stroke, Neuro-Oncology); end-user (Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, Academic & Research Institutions, Hospitals & Clinics, Contract Research Organizations); source (Cerebrospinal Fluid, Blood, Urine, Saliva, Tissue Biopsy, Hair Follicles); product & service (Assay Kits, Reagents & Consumables, Analyzers & Instruments, Software & Bioinformatics Tools, Biomarker Discovery Services, Contract Research Services), with market size and growth for every segment from 2025 to 2035.
Regional coverage: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, with forecasts for 26 countries.
Companies profiled include Quanterix, C2N Diagnostics, Denali Therapeutics, Alector, Prothena, Acumen Pharmaceuticals, Voyager Therapeutics, Neurocrine Biosciences, Amprion, Centogene.
授權報價
| Single User | $4,750 USD |
| Multi User | $5,750 USD |
| Enterprise / Global Site Licence | $6,750 USD |
目錄 Table of Contents
圖表清單 List of Tables & Figures
提及公司
常見問題
這份報告可以先索取樣本嗎?
可以。建議購買前先申請樣本,提出申請後約 2 個工作天內提供,您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算?
報告以美元標價,台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本(單人/多人/企業全站)價格不同,量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付?如何付款?
一般 3–7 個工作天交付,實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票,30 天內電匯付款即可。
量子訊息有限公司為 Market-Reports.com 在台灣的授權代理,提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們